Get the Stockscreener App
8.16
3.20%
-0.27
After Hours:
8.16
Amicus Therapeutics Inc stock is traded at $8.16, with a volume of 4.34M.
It is down -3.20% in the last 24 hours and down -14.01% over the past month.
See More
Previous Close:
$8.43
Open:
$8.31
24h Volume:
4.34M
Relative Volume:
1.94
Market Cap:
$2.64B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-24.00
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
-6.10%
1M Performance:
-14.01%
6M Performance:
-23.60%
1Y Performance:
-30.73%
1-Day Range:
$7.97
$8.31
1-Week Range:
$7.97
$8.71
52-Week Range:
$7.97
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
8.16 | 2.64B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
How To Trade (FOLD) - news.stocktradersdaily.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week LowShould You Sell? - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Fox Run Management L.L.C. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Trading Down 2.5%Time to Sell? - MarketBeat
Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment? - simplywall.st
Intech Investment Management LLC Has $1.18 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Treatment Market Size in 7MM is expected to grow at - openPR.com
Amicus Therapeutics stock hits 52-week low at $8.54 By Investing.com - Investing.com UK
Semanteon Capital Management LP Purchases 43,288 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Treatment Market reached US$ 1.39 billion in 2024 - openPR.com
Primecap Management Co. CA Sells 94,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Victory Capital Management Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Has $2.85 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
How to Take Advantage of moves in (FOLD) - Stock Traders Daily
Pompe Disease Treatment Market Size, Potential Scope 2033 By Key - openPR.com
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook - MSN
Great Lakes Advisors LLC Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Is Amicus Therapeutics Inc. (FOLD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey
Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade) (NASDAQ:FOLD) - Seeking Alpha
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Inceptionr LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 52-Week LowTime to Sell? - MarketBeat
Pompe Disease Treatment Market Size in the 7MM is expected - openPR
Essex Investment Management Co. LLC Has $2.18 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential - Insider Monkey
Amicus Therapeutics at Leerink Conference: Path to Profitability By Investing.com - Investing.com Canada
Amicus Therapeutics stock hits 52-week low at $8.78 By Investing.com - Investing.com Canada
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Sees Significant Drop in Short Interest - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):